首页> 外文OA文献 >PRM205 Systematic Review and Critical Appraisal of the Statistical Methods Used in Published Studies To Indirectly Compare Novel Anticoagulants (Noacs) With Warfarin for the Prevention of Stroke in Patients With Atrial Fibrillation (Af)

【2h】

PRM205 Systematic Review and Critical Appraisal of the Statistical Methods Used in Published Studies To Indirectly Compare Novel Anticoagulants (Noacs) With Warfarin for the Prevention of Stroke in Patients With Atrial Fibrillation (Af)

机译：PRM205对发表于研究中的方法进行系统的回顾和严格的评估，以间接比较新型抗凝剂（Noacs）与华法林预防房颤（Af）患者的中风

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Daacke I.M.;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group [J] . Pharithi Rebabonye B., Ranganathan Deepti, OBrien Jim, Irish journal of medical science . 2019,第1期

机译：处方是否正确？非瓣膜心房颤动患者的非维生素K拮抗剂抗凝血剂（NOAC）处方述评。心房颤动和卒中中非维生素K口腔抗凝血剂的心房颤动和评价安全规定（安全Noacs）组
2. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) (130, pg 138, 2014) [J] . Halperin Jonathan L., Hankey Graeme J., Wojdyla Daniel M., Circulation: An Official Journal of the American Heart Association . 2018,第25期

机译：Rivaroxaban的疗效和安全性与罗西沙巴少年患者的老年患者患者，口服，直接因子XA抑制与维生素K拮抗作用，用于预防心房颤动（Rocket AF）（130，Pg 138,2014）
3. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF) [J] . HalperinJ.L., HankeyG.J., WojdylaD.M., Circulation: An Official Journal of the American Heart Association . 2014,第2期

机译：利伐沙班对老年非瓣膜性心房颤动患者的利伐沙班与华法林的疗效和安全性相比，利伐沙班每日一次口服，口服直接因子xa抑制与维生素K拮抗作用相比较，以预防房颤中风和栓塞试验（ROCKET AF）
4. Incidence of Atrial Fibrillation After Percutaneous Closure of Patent Foramen Ovale and Small Atrial Septal Defects in Patients Presenting with Cryptogenic Stroke: A Case-Control Study [C] . R.F. Bonvini, R. Sztajzel, M. Righini, World Congress on Heart Disease . 2007

机译：用密码脑卒中患者经皮型卵形卵形卵形卵巢经皮和小间隔缺陷后心房颤动的发生率：案例对照研究
5. Cost effectiveness of warfarin in anticoagulant clinic after introduction of dabigatran for stroke prevention in atrial fibrillation patients in the United States [D] . Alhazami, Mai S. 2015

机译：在美国引入达比加群后预防心房颤动患者中风后华法林在抗凝临床中的成本效益
6. Critical appraisal and issues regarding generalisability of comparative effectiveness studies of NOACs in atrial fibrillation and their relation to clinical trial data: a systematic review [O] . Eveline M Bunge, Ben van Hout, Sylvia Haas, 2021

机译：关于心房颤动中巨乳巨乳比较效果研究的关键评价及其问题及其与临床试验数据的关系：系统审查
7. Editorial comment on ‘A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation’. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants? [O] . Shinichi Goto, Shinya Goto 2015

机译：编辑评论'一种小型方法间接比较益处：心房颤动患者口服抗血栓性疗法的风险'。是对充足性颤动患者的患者的当前剂量调整的抗凝，足以与新开发的非维生素K口腔抗凝剂进行比较吗？

PRM205 Systematic Review and Critical Appraisal of the Statistical Methods Used in Published Studies To Indirectly Compare Novel Anticoagulants (Noacs) With Warfarin for the Prevention of Stroke in Patients With Atrial Fibrillation (Af)

著录项

相似文献

相关主题

期刊订阅